Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

156 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this retrospective observational study is to collect only status survival data 30 days after the last dose of treatment of patients included in the initial protocol WYETH 3074A1-4448 / B1811030. The purpose is to estimate the survival status, 30 days after the last intake of tigecycline to patients hospitalized in ICU and treated by tigecycline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease

NCT03371095

Behcet's Disease Vasculitis

COMPLETED PHASE3

Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis

NCT05329090

IgA Vasculitis

ACTIVE_NOT_RECRUITING PHASE3

Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.

NCT04057703

Immune Thrombocytopenic Purpura Autoimmune Hemolytic Anemia Evan Syndrome +1 more

COMPLETED

Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis

NCT04871191

Granulomatosis with Polyangiitis Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

NOT_YET_RECRUITING PHASE3

Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases

NCT02280902

Immunologic and Inflammatory Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Survival Status at Day 30 After the Last Intake

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients included in the previous study WYETH 3074A1-4448 then Pfizer B1811030 for which mortality status was not known at the closure of this previous study